当前位置: 首页 > 期刊 > 《中华现代内科学杂志》 > 2006年第12期
编号：11329026
食管癌后程加速超分割三维适形放疗与食管癌后程加速超分割放疗的疗效评价
http://www.100md.com 《中华现代内科学杂志》 2006年第12期
放射剂量分次；适形；食管肿瘤,放射疗法,,],放射剂量分次；适形；食管肿瘤,放射疗法,1材料与方法,2结果,讨论,[参考文献
     食管癌后程加速超分割三维适形放疗与食管癌后程加速超分割放疗的疗效评价 (pdf)

    [摘要] 目的 评价后程加速超分割三维适形放疗与食管癌后程超分割放疗的疗效。方法 将54例食管鳞癌患者前瞻随机分组至后程加速超分割三维适形放疗(LCAH3DCRT)组和后程加速超分割放疗(LCAHRT)组。放疗方法均为前2/3天疗程普通模拟机定位常规放疗40 Gy，后1/3疗程LCAH3DCRT组改为CT模拟定位加速超分割三维适形放疗(1.6 Gy/次，2次/d，5 d/周，20～28 Gy)，总剂量为60～68 Gy，全疗程37～40天；LCAHRT组加速超分割放疗至上述相当剂量。 结果 LCAH3DCRT组和LCAHRT组5年生存率分别为31%和22%，LCAH3DCRT组生存率高于LCAHRT组(P=0.028)；3、4、5年无瘤生存率分别为34%、32%、31%和28%、26%、21%，LCAH3DCRT组无瘤生存率均高于LCAHRT组(P值均<0.05)。LCAH3DCRT组和LCAHRT组1、2、3、4、5年局部控制率分别为78%、73%、61%、59%、56%和58%、37%、30%、28%、25%，LCAH3DCRT组局部控制率高于LCAHRT组(P值均<0.05)。 结论 后程加速超分割三维适形放疗可作为食管癌的首选方法之一，它提高了5年生存率和局部控制率。

    [关键词] 放射剂量分次；适形；食管肿瘤/放射疗法

    Evaluation on latecourse accelerated hyperfractionated threedimensional conformal radiotherapy for esophageal carcinoma and latecourse accelerated hyperfractionated radiotherapy for esophageal carcinoma

    XU Yanjin.Tumor Department,Second Hospital of Liaohe Oil Field,Liaoning 124120,China

    [Abstract] Objective To evaluate the treatment results of latecourse accelerated hyperfractionated threedimensional conformal radiotherapy for esophageal carcinoma and latecourse accelerated hyperfractionated radiotherapy for esophageal carcinoma. Methods 54 esophageal carcinoma patients were divided randomly into two groups:LCAH3DCRT group27 patients were treated by conventional fractionated radiotherapy during the first twothirds of course with 40 Gy,then followed by hyperfraction 3DCRT with 20～28 Gy,1.6 Gy perfraction,2 times a day,5 days aweek,to a total dose of 60～68 Gy in 33～40 fractions over 37～40 days;LCAHRT group-27 patients were treated with the same method during the twothirds,then followed by accelerated hyperfractionated radiotherapy with the same dose.Results The 5-year survival rate was 31% and 22% in LCAH3DCRT and LCAHRT group,respectively(P=0.028).The 3-,4-,and 5-year tumorfree survival rate was 34%,32%,31% and 28%,26%,21% in LCAH3DCRT and LCAHRT group,respectively(all P<0.05).The 1-,2-,3-,4-,and 5-year local control rate was 78%,73%,61%,59%,56% and 58%,37%,30%,28%,25% in LCAH3DCRT and LCAHRT group,respectively(all P<0.05).Conclusion Latecourse accelerated hyperfractionated threedimensional conformal radiotherapy can be taken as the first choice for esophageal carcinoma:It can improve the 5-year survival and local control rate. ......

您现在查看是摘要页，全文长 9049 字符。